8-K: Helius Medical Technologies Regains Nasdaq Bid Price Compliance, Equity Rule Remains a Hurdle

Helius Medical Technologies, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, though it still needs to meet the equity rule by June 30, 2025.

Summary

• Helius Medical Technologies, Inc. (HSDT) received formal notification from The Nasdaq Stock Market LLC on June 3, 2025, confirming compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of at least $1.00 per share.
• The company had previously been granted an extension until June 30, 2025, to regain compliance with Nasdaq's Equity Rule 5550(b)(1).
• The Nasdaq Listing Qualifications hearing process will remain open until Helius demonstrates compliance with all continued listing requirements, including the Equity Rule.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company resolved one significant listing compliance issue (bid price), which is a positive step. However, the lingering non-compliance with the equity rule and the open hearing process introduce continued uncertainty, preventing a higher score.

Positives

• Helius Medical Technologies has successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, removing an immediate delisting threat related to this specific rule.

Negatives

• The company remains non-compliant with Nasdaq Listing Rule 5550(b)(1), the equity requirement, and must regain compliance by June 30, 2025.
• The Nasdaq Listing Qualifications hearing process remains open, indicating ongoing scrutiny until full compliance with all listing requirements is achieved.

Risks

• Failure to regain compliance with Nasdaq's Equity Rule 5550(b)(1) by the June 30, 2025 deadline could result in the company's common stock being delisted from The Nasdaq Capital Market.
• The ongoing Nasdaq listing qualifications process creates uncertainty regarding the company's long-term listing status.

Future Outlook

The company's future outlook is focused on its ability to achieve and maintain full compliance with all Nasdaq listing rules, specifically the remaining equity requirement by the June 30, 2025 deadline.

Management Comments

• Helius Medical Technologies announced that it has evidenced full compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules 5550(a)(2).

Industry Context

Helius Medical Technologies operates in the neurotech and medical device industry, specializing in a novel therapeutic neuromodulation approach for balance and gait deficits, with its primary commercial product being the Portable Neuromodulation Stimulator (PoNS).

Stakeholder Impact

• Shareholders: The regaining of bid price compliance reduces immediate delisting risk, which is positive for shareholder value and liquidity. However, the remaining equity rule non-compliance continues to pose a risk to the company's listing status.
• Employees: Continued Nasdaq listing provides stability and visibility, which can positively impact employee morale and retention.
• Customers/Suppliers: No direct impact mentioned, but maintaining public listing can enhance company credibility.

Next Steps

• Helius Medical Technologies must regain compliance with Nasdaq Listing Rule 5550(b)(1) (the Equity Rule) by June 30, 2025.
• The company needs to demonstrate compliance with all of The Nasdaq Stock Market's continued listing requirements to close the Nasdaq Listing Qualifications hearing process.

Key Dates

Recommendation

Keywords

Helius Medical Technologies, Nasdaq, Listing Compliance, Bid Price Rule, Equity Rule, Neurotech, Medical Device, PoNS, HSDT